Aortic Stenosis Treatment in India & UAE

Aortic stenosis treatment in India from $4,000. Surgical aortic valve replacement and TAVR at Apollo, Medanta, Fortis. 93% success. Expert cardiologists and cardiac surgeons. Book now.

Estimated cost: $4,000 – $30,000 · Average stay: 4–10 days

Aortic stenosis — the progressive narrowing of the aortic valve opening — is the most common valvular heart disease in adults and the most frequent indication for cardiac surgery in elderly patients worldwide. The aortic valve normally has a functional area of 2.5–3.5 cm². When degenerative calcification progressively stiffens and thickens the valve leaflets, the opening narrows: "moderate" stenosis begins at 1.5 cm²; "severe" stenosis is below 1.0 cm². "Very severe" or "critical" stenosis below 0.6 cm² produces the maximum pressure gradient, severely obstructing left ventricular outflow.

The clinical progression of aortic stenosis follows a predictable and lethal pattern without treatment. After a long asymptomatic period during which the left ventricle compensates by hypertrophying (thickening), symptoms develop — the classic triad of angina, syncope, and heart failure (breathlessness). Once symptoms appear, the average survival without valve intervention is 2–3 years. This prognosis is worse than many common cancers. Prompt recognition and treatment of symptomatic severe aortic stenosis is therefore genuinely life-saving.

Treatment of aortic stenosis has been revolutionized over the past decade by transcatheter aortic valve implantation (TAVI/TAVR) — a catheter-based approach that avoids open-heart surgery and can be performed safely in elderly, high-risk patients who were previously denied treatment because surgical risk was judged prohibitive. TAVR is now extending to intermediate and low-risk patient populations, though surgical aortic valve replacement (SAVR) remains the gold standard for younger patients with long life expectancy.

India offers both SAVR (from $4,000–$8,000) and TAVR (from $20,000–$30,000) at world-class cardiac centers including Apollo Hospitals, Medanta – The Medicity, Fortis Escorts Heart Institute, and AIIMS Delhi — at prices that are 70–90% below Western equivalents and with outcomes data that is internationally competitive.

What Causes Aortic Stenosis and How Is Severity Assessed?

In adults over 65, the most common cause is degenerative calcific aortic stenosis — progressive calcium deposition on the aortic leaflets driven by the same atherosclerotic risk factors (dyslipidemia, hypertension, diabetes, smoking, chronic kidney disease) that cause coronary artery disease. Bicuspid aortic valve (a congenital defect where the valve has two leaflets instead of three — affecting 1–2% of the population) causes aortic stenosis 1–2 decades earlier than in tricuspid valves.

Severity is assessed by Doppler echocardiography: peak aortic velocity (above 4 m/s = severe), mean gradient (above 40 mmHg = severe), and calculated aortic valve area (below 1.0 cm² = severe). CT calcium scoring of the aortic valve provides additional severity grading particularly useful in "low-flow, low-gradient" aortic stenosis where Doppler measurements can be misleading.

Cardiac catheterization with simultaneous LV-aortic pressure measurement (the Gorlin formula) may be needed for discordant Doppler findings. Coronary angiography is performed in all adults considering aortic valve surgery or TAVR, as co-existent coronary artery disease is present in 40–50% and must be addressed simultaneously or beforehand.

Who Needs Treatment for Aortic Stenosis?

Treatment is indicated for all symptomatic patients with severe aortic stenosis — once symptoms (angina, syncope, dyspnea) develop, the natural history is rapid deterioration and high mortality without intervention. Asymptomatic patients with severe aortic stenosis are considered for early intervention when: LV function is declining (EF below 50%); the peak aortic velocity is very high (above 5 m/s); severe calcification load on CT suggests accelerating progression; or the patient is about to undergo cardiac surgery for another indication.

The choice between SAVR and TAVR is determined by the Heart Team based on: patient age (younger patients favor SAVR for longer valve durability; older patients favor TAVR for lower procedural risk); surgical risk score (high surgical risk favors TAVR); anatomical suitability (annulus size, coronary height, aortic access for TAVR; calcification pattern); co-existing coronary disease (more easily treated at SAVR); and patient preference (avoiding surgery vs. accepting anticoagulation for mechanical SAVR).

Treatment Options for Aortic Stenosis

There is no effective medical therapy for aortic stenosis — statins do not slow progression despite the atherosclerotic pathophysiology; the calcification process is a distinct mechanism from arterial plaque formation. The only effective treatment is mechanical opening or replacement of the valve.

Surgical Aortic Valve Replacement (SAVR): Open-heart surgery under cardiopulmonary bypass. The stenotic native valve is excised; a prosthetic valve (mechanical or bioprosthetic tissue) is sutured in its place. SAVR provides excellent hemodynamics, excellent long-term durability (mechanical valves last lifelong; tissue valves 15–20 years), and low reoperation risk. Standard approach through median sternotomy; minimally invasive approaches (partial upper sternotomy, right mini-thoracotomy) available at specialist centers. Best for patients under 75 with acceptable surgical risk.

Transcatheter Aortic Valve Implantation (TAVI/TAVR): A compressed bioprosthetic valve is crimped onto a catheter and delivered via the femoral artery (or, if femoral access is unsuitable, via the subclavian artery or direct aortic approach). The valve is positioned within the diseased native valve and expanded — either by balloon inflation (balloon-expandable valves: Edwards SAPIEN 3) or self-expansion (self-expanding valves: Medtronic Evolut PRO+, Boston Scientific Acurate neo). The native valve is pushed aside and the new valve immediately functions. No sternotomy, no general anesthesia (often performed under conscious sedation), no cardiopulmonary bypass. Hospital stay 1–3 days.

Balloon Aortic Valvuloplasty (BAV): Temporary palliation — balloon dilation of the calcified valve provides short-term improvement (3–6 months) before inevitable restenosis. Used as a bridge to SAVR or TAVR in hemodynamically unstable patients.

Procedure Steps

1. Pre-operative workup: echocardiography (severity assessment, LV function, co-existing valve disease); cardiac CT (TAVR planning: annulus dimensions, access route, coronary heights, calcification load); coronary angiography; pulmonary function; creatinine and GFR.
2. Heart Team assessment: interventional cardiologist and cardiac surgeon jointly review all data; SAVR vs. TAVR vs. medical management decision; STS/EuroSCORE II surgical risk calculation.
3. SAVR: median sternotomy; cardiopulmonary bypass; native valve excised; prosthetic valve sutured in annulus; bypass weaned; TEE confirms valve function.
4. TAVR: local anesthesia or conscious sedation; femoral arterial access; delivery catheter advanced to aortic valve; valve deployed under fluoroscopy and TEE guidance; catheter removed; access site closed.
5. Post-operative monitoring: telemetry for 24–48 hours (heart block risk — complete heart block requiring pacemaker occurs in 5–20% of TAVR and 2–5% of SAVR cases, depending on valve type and pre-existing conduction abnormalities).
6. Anticoagulation/antiplatelet: TAVR patients typically receive dual antiplatelet (aspirin + clopidogrel for 3 months), then aspirin alone; SAVR mechanical valve patients require lifelong warfarin.
7. Discharge: TAVR day 2–3; SAVR day 7–10.

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

United States — $40,000 – $100,000 — Baseline

United Kingdom — $20,000 – $50,000 — ~50% savings vs. USA

India — $4,000 – $30,000 (SAVR or TAVR) — Up to 90% savings vs. USA

UAE — $15,000 – $55,000 — ~50% savings vs. USA

SAVR packages in India: $4,000–$8,000 with tissue valve; $5,000–$9,000 with mechanical valve. TAVR packages: $20,000–$30,000 (major cost is the valve device itself — Edwards SAPIEN, Medtronic Evolut — which costs $10,000–$15,000 at Indian import prices). TAVR in India remains 50–75% below US pricing despite the high device cost. Gaf Healthcare confirms valve type availability and total package pricing before booking.

Recovery & Follow-up

SAVR recovery: ICU 1–2 days; hospital 7–10 days; sternal healing 6–8 weeks; return to activity 8–12 weeks.

TAVR recovery is dramatically faster: procedure 1–2 hours; hospital stay 2–3 days; walking the next morning; return home in 3–5 days; light activity immediately; full activity in 2–4 weeks. This rapid recovery is the major advantage of TAVR — particularly for elderly patients with multiple comorbidities for whom a prolonged recovery is hazardous.

Post-treatment: echocardiography at 1 month, 1 year, and annually thereafter. CT aortography at 5 years for TAVR patients to assess valve position and paravalvular leak progression.

Recovery Tips

• Take antiplatelet medication (aspirin, clopidogrel after TAVR) without fail — valve thrombosis is prevented by platelet inhibition.
• Mechanical SAVR patients: INR monitoring weekly initially; carry warfarin card; avoid large changes in vitamin K intake.
• Report any breathlessness, palpitations, ankle swelling, or fever — may indicate valve thrombosis, regurgitation, or endocarditis.
• Annual echocardiogram monitors valve gradient, regurgitation, and LV function.
• Endocarditis prophylaxis before dental procedures for prosthetic valve recipients.
• Cardiac rehabilitation from 6 weeks (SAVR) or 2 weeks (TAVR).

Risks & Complications

SAVR mortality: 1–2% for isolated AVR in good-risk patients; higher with concurrent procedures, reduced LV function, or high surgical risk score. TAVR mortality: 1–3% for low-risk patients (PARTNER 3 trial: 1.0% at 30 days). TAVR-specific risks: permanent pacemaker requirement (5–20% depending on valve type and pre-existing conduction disease); paravalvular regurgitation (mild in 20–30%, moderate in 5%); stroke (1–2%); vascular access complication (2–3%); and valve migration/embolization (rare — less than 0.5%). SAVR-specific risks: complete heart block (2–5%), stroke (1–2%), sternal wound infection (1–2%), bleeding.

Why GAF Healthcare

Gaf Healthcare's cardiac team facilitates the full Heart Team assessment process for aortic stenosis patients — arranging the echocardiogram, cardiac CT (crucial for TAVR planning), and coronary angiography at partner hospitals before the surgical/interventional consultation. We coordinate both SAVR and TAVR packages at India's and UAE's leading aortic valve programs. Patients receive a complete written treatment recommendation from the Heart Team before committing to travel.

Frequently Asked Questions

Can aortic stenosis be treated without open-heart surgery?

Yes — TAVR (transcatheter aortic valve implantation) replaces the stenotic aortic valve through a catheter in the leg artery, with no sternotomy, no cardiopulmonary bypass, and no general anesthesia in most cases. It is now approved for all risk categories and is preferred over surgery in most patients over 75 and all high-surgical-risk patients.

How long does a TAVR valve last?

Data from the earliest TAVR cases (now 15+ years of follow-up) shows structural valve deterioration occurring in 1–3% of patients at 10 years. Long-term durability is still being evaluated, but 5–10 year outcomes are excellent. TAVR within TAVR (placing a new TAVR valve inside a failing TAVR valve) is now well-established, extending the lifespan of TAVR therapy.

Is aortic stenosis hereditary?

Bicuspid aortic valve — the most common cause of aortic stenosis in patients under 70 — is hereditary in approximately 10% of first-degree relatives. Degenerative calcific aortic stenosis shares risk factors with atherosclerosis, which has a partial genetic component. Screening echocardiography for first-degree relatives of bicuspid aortic valve patients is recommended.

What is the cost of aortic stenosis treatment in India?

Surgical AVR (SAVR) costs $4,000–$9,000 in India; TAVR costs $20,000–$30,000. Compare with $40,000–$100,000 in the USA for the same procedures. The aortic valve device cost dominates TAVR pricing; India imports the same Edwards SAPIEN and Medtronic Evolut valves used globally.